A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or
Fitbit CEO James Park Tracks His Workouts, Naturally
Not exactly what James Park wants to hear—but it’s close. On a balmy January morning, Park is in a grassy
Safety Profile for Novel CGRP Beats Standard of Care
Atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist that’s been in development as a preventive treatment for chronic migraine,